In terms of IDH mutation status, FAP level was slightly lower in patients with IDH-mutant glioma compared to the IDH-wildtype, but the difference was not statistically significant (Fig. 1IIIa, P = 0.1634). This evidence concerns the gene IDH1 and central nervous system cancer.